Cargando…
Detailed analysis of retinal morphology in patients with diabetic macular edema (DME) randomized to ranibizumab or triamcinolone treatment
PURPOSE: Our purpose was to compare the impact in diabetic macula edema (DME) of two intravitreal drugs (0.5 mg ranibizumab vs. 8 mg triamcinolone) on changes in retinal morphology in spectral-domain optical coherence tomography (SD OCT) images, color fundus photography (CF) and fluorescein angiogra...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Berlin Heidelberg
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5748439/ https://www.ncbi.nlm.nih.gov/pubmed/29080915 http://dx.doi.org/10.1007/s00417-017-3828-1 |
_version_ | 1783289399464689664 |
---|---|
author | Karst, Sonja G. Lammer, Jan Mitsch, Christoph Schober, Manuela Mehta, Janhvi Scholda, Christoph Kundi, Michael Kriechbaum, Katharina Schmidt-Erfurth, Ursula |
author_facet | Karst, Sonja G. Lammer, Jan Mitsch, Christoph Schober, Manuela Mehta, Janhvi Scholda, Christoph Kundi, Michael Kriechbaum, Katharina Schmidt-Erfurth, Ursula |
author_sort | Karst, Sonja G. |
collection | PubMed |
description | PURPOSE: Our purpose was to compare the impact in diabetic macula edema (DME) of two intravitreal drugs (0.5 mg ranibizumab vs. 8 mg triamcinolone) on changes in retinal morphology in spectral-domain optical coherence tomography (SD OCT) images, color fundus photography (CF) and fluorescein angiography (FA) images during a 1-year follow-up. METHODS: Post hoc analysis was conducted of morphologic characteristics in OCT, FA and CF images of eyes with a center involving DME that were included in a prospective double-masked randomized trial. Eligible patients were divided at random into two groups receiving either pro re nata treatment with 0.5 mg ranibizumab or 8 mg triamcinolone after a fixed loading dose. OCT and CF images were acquired at monthly visits and FA images every three months. RESULTS: Twenty-five eyes of 25 patients (ranibizumab: n = 10; triamcinolone: n = 15) were included in this study. Patients treated with ranibizumab showed better visual acuity results after 12 months than patients receiving triamcinolone (p = 0.015) although edema reduction was similar (p = 0.426) in both groups. The initial effect on macular edema shedding after a single ranibizumab injection could be amplified with the following two injections of the loading dose. After a single injection of triamcinolone the beneficial initial effect on the macula edema faded within 3 months. Subretinal fluid and INL cystoid spaces diminished early in the course of treatment while fluid accumulation in the ONL seemed to be more persistent in both treatment arms. In FA, the area of leakage diminished significantly in both treatment arms. After repeated injections the morphologic OCT and FA characteristics of the treatment arms converged. CONCLUSIONS: Despite the higher dosage of triamcinolone, both therapies were safe and effective for treating diabetic macular edema. Fluid accumulation in the INL and subretinal space was more responsive to therapy than fluid accumulation in the ONL. Clinicaltrials.gov: NCT00682539. |
format | Online Article Text |
id | pubmed-5748439 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | Springer Berlin Heidelberg |
record_format | MEDLINE/PubMed |
spelling | pubmed-57484392018-01-19 Detailed analysis of retinal morphology in patients with diabetic macular edema (DME) randomized to ranibizumab or triamcinolone treatment Karst, Sonja G. Lammer, Jan Mitsch, Christoph Schober, Manuela Mehta, Janhvi Scholda, Christoph Kundi, Michael Kriechbaum, Katharina Schmidt-Erfurth, Ursula Graefes Arch Clin Exp Ophthalmol Retinal Disorders PURPOSE: Our purpose was to compare the impact in diabetic macula edema (DME) of two intravitreal drugs (0.5 mg ranibizumab vs. 8 mg triamcinolone) on changes in retinal morphology in spectral-domain optical coherence tomography (SD OCT) images, color fundus photography (CF) and fluorescein angiography (FA) images during a 1-year follow-up. METHODS: Post hoc analysis was conducted of morphologic characteristics in OCT, FA and CF images of eyes with a center involving DME that were included in a prospective double-masked randomized trial. Eligible patients were divided at random into two groups receiving either pro re nata treatment with 0.5 mg ranibizumab or 8 mg triamcinolone after a fixed loading dose. OCT and CF images were acquired at monthly visits and FA images every three months. RESULTS: Twenty-five eyes of 25 patients (ranibizumab: n = 10; triamcinolone: n = 15) were included in this study. Patients treated with ranibizumab showed better visual acuity results after 12 months than patients receiving triamcinolone (p = 0.015) although edema reduction was similar (p = 0.426) in both groups. The initial effect on macular edema shedding after a single ranibizumab injection could be amplified with the following two injections of the loading dose. After a single injection of triamcinolone the beneficial initial effect on the macula edema faded within 3 months. Subretinal fluid and INL cystoid spaces diminished early in the course of treatment while fluid accumulation in the ONL seemed to be more persistent in both treatment arms. In FA, the area of leakage diminished significantly in both treatment arms. After repeated injections the morphologic OCT and FA characteristics of the treatment arms converged. CONCLUSIONS: Despite the higher dosage of triamcinolone, both therapies were safe and effective for treating diabetic macular edema. Fluid accumulation in the INL and subretinal space was more responsive to therapy than fluid accumulation in the ONL. Clinicaltrials.gov: NCT00682539. Springer Berlin Heidelberg 2017-10-28 2018 /pmc/articles/PMC5748439/ /pubmed/29080915 http://dx.doi.org/10.1007/s00417-017-3828-1 Text en © The Author(s) 2017 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. |
spellingShingle | Retinal Disorders Karst, Sonja G. Lammer, Jan Mitsch, Christoph Schober, Manuela Mehta, Janhvi Scholda, Christoph Kundi, Michael Kriechbaum, Katharina Schmidt-Erfurth, Ursula Detailed analysis of retinal morphology in patients with diabetic macular edema (DME) randomized to ranibizumab or triamcinolone treatment |
title | Detailed analysis of retinal morphology in patients with diabetic macular edema (DME) randomized to ranibizumab or triamcinolone treatment |
title_full | Detailed analysis of retinal morphology in patients with diabetic macular edema (DME) randomized to ranibizumab or triamcinolone treatment |
title_fullStr | Detailed analysis of retinal morphology in patients with diabetic macular edema (DME) randomized to ranibizumab or triamcinolone treatment |
title_full_unstemmed | Detailed analysis of retinal morphology in patients with diabetic macular edema (DME) randomized to ranibizumab or triamcinolone treatment |
title_short | Detailed analysis of retinal morphology in patients with diabetic macular edema (DME) randomized to ranibizumab or triamcinolone treatment |
title_sort | detailed analysis of retinal morphology in patients with diabetic macular edema (dme) randomized to ranibizumab or triamcinolone treatment |
topic | Retinal Disorders |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5748439/ https://www.ncbi.nlm.nih.gov/pubmed/29080915 http://dx.doi.org/10.1007/s00417-017-3828-1 |
work_keys_str_mv | AT karstsonjag detailedanalysisofretinalmorphologyinpatientswithdiabeticmacularedemadmerandomizedtoranibizumabortriamcinolonetreatment AT lammerjan detailedanalysisofretinalmorphologyinpatientswithdiabeticmacularedemadmerandomizedtoranibizumabortriamcinolonetreatment AT mitschchristoph detailedanalysisofretinalmorphologyinpatientswithdiabeticmacularedemadmerandomizedtoranibizumabortriamcinolonetreatment AT schobermanuela detailedanalysisofretinalmorphologyinpatientswithdiabeticmacularedemadmerandomizedtoranibizumabortriamcinolonetreatment AT mehtajanhvi detailedanalysisofretinalmorphologyinpatientswithdiabeticmacularedemadmerandomizedtoranibizumabortriamcinolonetreatment AT scholdachristoph detailedanalysisofretinalmorphologyinpatientswithdiabeticmacularedemadmerandomizedtoranibizumabortriamcinolonetreatment AT kundimichael detailedanalysisofretinalmorphologyinpatientswithdiabeticmacularedemadmerandomizedtoranibizumabortriamcinolonetreatment AT kriechbaumkatharina detailedanalysisofretinalmorphologyinpatientswithdiabeticmacularedemadmerandomizedtoranibizumabortriamcinolonetreatment AT schmidterfurthursula detailedanalysisofretinalmorphologyinpatientswithdiabeticmacularedemadmerandomizedtoranibizumabortriamcinolonetreatment |